Headlines
Clinical Trials
| Protocol Number | Title | Study Status | PI | Website | Section | |
|---|---|---|---|---|---|---|
| Phase 1 | ||||||
| 08C0007 | A Phase I Study of Ipilimumab (Anti-CTLA4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer | Currently Accruing |
Melinda, Merchant |
Link |
Solid Tumors Pharmacology and Experimental Therapeutics |
|
| 08C0123 | A Phase 1, Multi-Center, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL) | Not Currently Accruing |
Wayne, Alan |
Link |
Hematologic Diseases Pharmacology and Experimental Therapeutics |
|
| 11C0047 | Phase I trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors | Currently Accruing |
Widemann, Brigitte |
Link |
Solid Tumors Neuro-Oncology Pharmacology and Experimental Therapeutics |
|
| 11C0161 | A Phase 1 Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor AZD6244 Hydrogen Sulfate (Selumetinib Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | Currently Accruing |
Widemann, Brigitte |
Link |
Pharmacology and Experimental Therapeutics Neurofibromatosis |
|
| 11C0053 | Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors | Not Currently Accruing |
Widemann, Brigitte |
Link |
Pharmacology and Experimental Therapeutics Solid Tumors |
|
| 12C0208 | Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors | Currently Accruing |
Widemann, Brigitte |
Pharmacology and Experimental Therapeutics Solid Tumors |
||
| 13C0042 | ADVL1211: A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors | Currently Accruing |
Widemann, Brigitte |
Solid Tumors Pharmacology and Experimental Therapeutics Neuro-Oncology |
||
| Phase 1 & 2 | ||||||
| 07C0189 | Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma | Currently Accruing |
Widemann, Brigitte |
Link |
Medullary Thyroid Carcinoma Pharmacology and Experimental Therapeutics |
|
| 10C0178 | A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma | Currently Accruing |
Widemann, Brigitte |
Link |
Solid Tumors Hematologic Diseases Pharmacology and Experimental Therapeutics |
|
| 12C0135 | Phase I/II Trial of Mithramycin in Children and Adults with Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript (Phase II) | Currently Accruing |
Widemann, Brigitte |
Link |
Solid Tumors Pharmacology and Experimental Therapeutics |
|
| Phase 2 | ||||||
| 12C0098 | A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed / Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma | Currently Accruing |
Widemann, Brigitte |
Link |
Pharmacology and Experimental Therapeutics Solid Tumors |
|
| 12C0148 | SARC016: Phase II Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors | Currently Accruing |
Widemann, Brigitte |
Link |
Pharmacology and Experimental Therapeutics Neurofibromatosis |
|
| Natural History | ||||||
| 12C0178 | Longitudinal Assessment and Natural History Study of Children and Young Adults With Medullary Thyroid Carcinoma | Currently Accruing |
Widemann, Brigitte |
Link |
Medullary Thyroid Carcinoma Pharmacology and Experimental Therapeutics |
|
This Page Last Reviewed on
April 28, 2011
About CCR | Clinical Trials | Research | Employment | Initiatives | News | Events | Site Privacy Policy | Accessibility
A Service of the National Cancer Institute
